Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

It’s the guns, stupid

Gun violence in the US – a public health issue – can be better understood through three points

Spotlight interview: 15 minutes on healthcare advertising

Marie Little, Managing Director, OPEN Health Patient & Brand Communications takes 15 minutes to answer some key questions on healthcare advertising

OPEN Health

- PMLiVE

The heart of Lucid’s new HQ is under construction

With just 3 weeks until the move, the new kitchen and bar are being installed in Middlesex House.

Lucid Group Communications Limited

- PMLiVE

Darwinian leadership in the life sciences industry

Good leadership is about adapting to the exceptional features of our industry

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

- PMLiVE

Significant gaps remain in UK’s no-deal Brexit prep, says NAO report

Medicine supply still under threat despite preparedness programme

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

- PMLiVE

Declining childhood vaccination rates ring alarm bells in England

UK thought to have second-lowest MMR vaccination in Europe

Bluedog boosts its senior team with the appointment of its new Technical Director

Bluedog, a Lucid Group company, is set to create more magic for its clients with the appointment of Jonathan Andrew as its new technical director.Jonathan has a proven track record...

Lucid Group Communications Limited

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

- PMLiVE

Building European biotech firms to rival those of the US

PME speaks to Richard Mason on how drug discovery is evolving

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links